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Glaucoma is a disease characterized by the combination of
damage to the optic nerve and loss of visual field, primarily
due to the death of retinal ganglion cells and gradual
cupping of the optic nerve head [1]. Elevated intraocular
pressure (IOP) is not only a main characteristic of glauco-
matous disease, but also a significant etiologic factor. Al-
though the exact etiology of glaucoma has not been com-
pletely understood, vascular factors that decrease ocular
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The purpose of this study was to evaluate both the intraocular pressure (IOP)-decreasing and
neuroprotective effects of Rescula (0.12% unoprostone isopropyl) as an alternative therapy to beta-
blockers with a long-term drift effect in patients with glaucoma. Twenty-eight patients with unilateral or
bilateral glaucoma were treated with Rescula instead of the original beta-blocker therapy. IOP was
measured using a Goldmann applanation tonometer, and visual field defects were evaluated quantitatively
by Humphrey automatic perimetry central 30-2 threshold test. The mean follow-up time was at least
1 year. Rescula achieved a significant (p = 0.00001) and long-lasting reduction in IOP (from 20.78 ± 2.71 to
17.14 ± 2.70 mmHg) in patients with open-angle glaucoma after 12 months of follow-up. It also demonstrated
a significant (p = 0.02) IOP-reducing effect (from 20.67 ± 3.60 to 16.36 ± 3.67 mmHg) in patients with angle-
closure glaucoma 12 months later. The mean deviation of visual field defects changed from –13.27 dB
baseline to –10.64 dB at 12 months as evaluated by Humphrey field analyzer II central 30-2 threshold test
after Rescula; however, there was no statistical difference (p = 0.098). Our results showed that Rescula has
a significant IOP-reducing effect as an alternative therapy to beta-blockers with long-term drift effect in
patients with open-angle and angle-closure glaucoma. However, a neuroprotective effect to prevent further
progression of the visual field defect in patients with glaucoma was not demonstrated in this study.
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blood flow and result in subsequent dysfunction of
neuroprotection are considered to be important factors in
the development of the disease [2–6]. Since glaucoma is a
multifaceted disease, there is significant research in process
to develop the regimens that not only lower IOP, but also
address other physiologic aspects of the disease, particularly
in neuroprotective and vascular dysfunction.
Current treatment strategies for glaucoma and ocular
hypertension (OHT) are primarily aimed at decreasing
elevated IOP. Topical beta-blockers are usually the first line
of ocular hypotensive therapy. If target IOP is not reached
after a period of monotherapy, switching treatment is used
to obtain the desired IOP-decreasing effect, especially
switching to drugs with different mechanisms [7].
© 2006 Elsevier. All rights reserved.
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Unoprostone isopropyl is a docosanoid derived from a
metabolite of a primary prostaglandin, 13,14-dihydro-15-
ketoprostaglandin. It was found to have a significant IOP-
lowering effect and was as effective as timolol in reducing
IOP in primary open-angle glaucoma (POAG) [8,9]. It acts
by increasing uveoscleral outflow in a similar manner to
latanoprost [10,11]. Although the adjunctive use of uno-
prostone has a significant added IOP-decreasing effect in
patients with POAG or OHT treated with beta-blockers
alone, we used unoprostone alone (unoprostone isopropyl
0.12%, Rescula) as a replacement, not as adjunctive therapy,
to evaluate its long-term efficacy and safety.
In this study, we collected topical beta-blocker-treated
glaucoma patients with so-called long-term drift effect.
Long-term drift is a phenomenon that occurs in patients
with extended use of beta-blockers. There is a slow, but real
upward “drift” in IOP, as the response to beta receptors is
affected by constant exposure to an agonist. We evaluated
the IOP-lowering effect and visual field preservation of
Rescula as monotherapy to substitute beta-blockers with
long-term drift effect in glaucoma patients.
PATIENTS AND METHODS
This study was prospectively carried out at the Kaohsiung
Medical University Hospital, Taiwan. All patients enrolled
in the study were followed in a glaucoma clinic and treated
initially with beta-blockers, including 0.5% Bunolgan
(levobunolol), 0.5% Timoptol XE (timolol), and 2% Arteoptic
(carteolol) for at least 1 year. The types of glaucoma in these
patients included POAG, chronic angle-closure glaucoma
(CACG), normal tension glaucoma (NTG), and OHT. The
reasons why beta-blockers were discontinued included
elevated IOP (> 21 mmHg) with mild-to-moderate visual
field loss (mean deviation of visual field defect between –3
and –25 dB ) and progressive visual field defect with normal
IOP () 21 mmHg). Patients received an alternative therapy
with Rescula (unoprostone 0.12%) and were consecutively
collected at the glaucoma clinic. Rescula was used twice a
day, at 8 a.m. and 8 p.m., with the same frequency as beta-
blockers. Baseline IOP was defined at the time when beta
blockers were stopped. To prevent irreversible damage to
the patients, we switched the eye drops without a washout
period. Instead, we ignored the IOPs within the first month
when two kinds of eye drops were overlapping. After
switching to Rescula, IOPs were collected during the 1st, 3rd,
6th and 12th months. IOPs were measured thrice for each eye
at the same time, and they were measured at different times,
at 9 a.m., 1 p.m. and 5 p.m., on the same day for correction
of diurnal changes. The IOPs of each time point of visiting
were averaged. Visual field defects were determined by the
Humphrey automatic perimetry central 30-2 threshold test.
The mean deviations were collected before Rescula treatment
and after using Rescula for 6, 12 and 24 months.
Statistical analysis
Statistical comparison of IOP reduction and visual field
defect was performed by Student’s paired t test.
RESULTS
Patient demographics
A total of 28 patients were enrolled in this study; 30 eyes of
17 patients were open-angle glaucoma (12 POAG, 3 OHT,
2 NTG), 15 eyes of 10 patients were angle-closure glaucoma, and
both eyes of one patient had a combination of open-angle and
angle-closure glaucoma. There were 6 male and 11 female
patients in the open-angle glaucoma group, and 6 male and
4 female patients in the angle-closure glaucoma group.
The mean age of the patients in the open-angle glaucoma
group (48.71 ± 14.85 years) was younger than that in the
angle-closure glaucoma group (65.1 ± 6.24 years) (Table 1).
Efficacy in lowering intraocular pressure
In the present study, changes in IOP in the right eyes of all
patients decreased significantly (p = 0.013) after shifting to
Rescula, from 21.31 ±  3.17 to 17.90 ±  1.89 mmHg; in the
left eyes, IOP decreased significantly (p = 0.025) from 20.30
± 2.63 to 17.53 ± 3.19 mmHg. Since the IOP decreases were
significant in both right and left eyes, we used all the IOP
values of the patients who were divided into the two sub-
groups — open-angle and angle-closure glaucoma. Rescula
showed a significant (p = 0.00001) and long-lasting IOP-
lowering effect (from 20.78 ±  2.71 to 17.14 ± 2.70 mmHg)
in patients with open-angle glaucoma after 12 months’
follow-up. It also demonstrated a significant (p = 0.02) IOP-
reducing effect (from 20.67 ± 3.60 to 16.36 ± 3.67 mmHg) in
patients with angle-closure glaucoma after 12 months’
follow-up. Changes in IOP during the study periods are
presented in Table 2.
Changes in visual field defect
The mean deviation of visual field defect changed from
–13.27 dB (baseline) to –10.64 dB (12 months after treatment
with Rescula). There was no significant difference in the
visual field defect (p = 0.098).
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DISCUSSION
Rescula (unoprostone isopropyl) is generally prescribed to
patients with open-angle glaucoma. In our study, Rescula
was prescribed not only to patients with open-angle
glaucoma, but also to patients with angle-closure glaucoma.
The results revealed that Rescula is effective in both open-
angle (p = 0.00001) and angle-closure glaucoma (p = 0.02)
after 12 months’ follow-up.
In general, beta-blockers have an excellent IOP-
decreasing effect and are commonly used as the first-line
IOP-lowering agent. Rescula is usually used as an adjunctive
therapy to beta-blockers, but not as a replacement therapy.
There were two reasons for using Rescula both as mono-
therapy and as a replacement of beta-blockers instead of
adjunctive therapy. First, all our patients had used beta-
blockers for at least 1 year. Initially, the IOP-lowering effect
was good; however, IOP elevated gradually due to the
long-term drift effect. In this situation, changing the eye
drops or adding a second eye drop to lower IOP might be
the next step. It was decided to stop the beta-blockers.
Second, glaucoma is a chronic disease and requires long-
term use of hypotensive medication. Thus, patient com-
pliance is one of the major factors affecting long-term prog-
nosis. The more convenient and simple the medication, the
better is the compliance of patients. Monotherapy is still
the best choice. As an alternative therapy, prostaglandin
analog is usually the first choice of treatment. Although
other prostaglandin analogs such as latanoprost may have
better IOP-lowering effects than Rescula, Rescula has few of
the local cosmetic side effects (such as conjunctival con-
gestion and permanent melanin pigmentation of the eye-
lids and iris) that patients are seriously concerned about.
Thus, Rescula was chosen as the alternative agent and the
patients remained on monotherapy at the same frequency
to observe if IOP would decrease as expected. The results
revealed that Rescula can lower IOP effectively after
switching from beta-blockers.
Unoprostone may have a neuroprotective effect because
it can counteract endothelin-1-induced vasoconstriction in
both animal and human models [12–14], increase ocular
blood flow and blood flow velocity in rabbits and humans
[12,15–18], and protect against ischemia and photoreceptor
damage in rats [19–21], as well as against glutamate-
mediated neuronal death in an in vitro model [22]. We
evaluated the changes of visual field defect before and after
Rescula treatment to ascertain whether Rescula can work as
a preserver of the visual field. The results revealed a minimal
improvement in visual field defect, but there was no
significant difference (p = 0.098). Since visual field defect is
generally irreversible, the preservation of visual defect
after 12 months’ follow-up in this study may suggest that
Table 1. Characteristics of the glaucoma patients
Type of glaucoma
Open angle
Angle-closure Combined
POAG OHT NTG
No. of patients (eyes) 12 (21) 3 (5) 2 (4) 10 (15) 1 (2)
Sex (male/female) 6/11 6/4 1/0
Mean age (yr) 48.71 ± 14.85 65.1 ± 6.24 66
Bilateral/unilateral 13/4 5/5 1/0
POAG = primary open-angle glaucoma; OHT = ocular hypertension; NTG = normal tension glaucoma.
Table 2. Intraocular pressure before and after Rescula treatment
Open-angle glaucoma p Angle-closure glaucoma p
Before Rescula (mmHg) 20.78 ± 2.71 20.67 ± 3.60
After Rescula (mmHg)
4 wk 19.09 ± 3.49 0.0007 17.50 ± 3.68 0.003
12 wk 18.86 ± 2.36 0.0037 17.00 ± 3.58 0.02
24 wk 18.87 ± 4.15 0.0047 16.26 ± 3.00 0.01
48 wk 17.14 ± 2.70 0.00001 16.36 ± 3.67 0.02
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Rescula might have a neuroprotective effect to prevent its
further progression. Unfortunately, due to the fact that
there was no control group in this study, it is not possible to
conclude whether or not Rescula can preserve the visual
field and prevent further progression of the visual field
defect either by its IOP-decreasing effect or other neuro-
protective effects. Further study is warranted.
CONCLUSION
Rescula (0.12% unoprostone isopropyl) had significant
(p < 0.001) and long-lasting IOP-lowering effects in patients
with open-angle glaucoma in this study. Rescula also had a
significant (p = 0.02) IOP-reducing effect in patients with
angle-closure glaucoma. We suggest that Rescula can
provide an IOP-reducing effect as an alternative therapy to
beta-blockers in patients with open-angle glaucoma and
angle-closure glaucoma who suffer from the long-term
drift effect as a result of beta-blocker use.
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